Smallpox Vaccine LC16m8: Production, Properties, and Prospects
Open Access
- 28 September 2024
- journal article
- Published by Russian Research Anti-Plague Institute Microbe in Problems of Particularly Dangerous Infections
- No. 3,p. 42-50
Abstract
Abrogation of obligatory vaccination against smallpox has lead to degradation of herd immunity and humanity has become vulnerable to long known infections, such as monkeypox (mpox), cowpox, camelpox, buffalopox and emerging ones, caused by viruses Alaska and Akhmeta. This situation demands availability of safe smallpox vaccines, the immunogenicity of which is comparable to vaccines used in the period of smallpox elimination. The aim of this review is to analyze the research of Japanese scientists on the production and investigation of properties of the smallpox vaccine LC16m8 and to assess further prospects for the use of the LC16m8 strain. The LC16m8 vaccine was obtained based on one of the Lister clones and has been licensed in Japan since 1975. Whole-genome sequencing revealed that its main difference from the genome of the original strain is a mutation in the B5R gene, which determines its safety for laboratory animals and humans. The immunogenicity of the vaccine based on this strain is comparable to the immunogenicity of the first generation vaccines: Lister, Dryvax, Ikeda. According to WHO recommendations, second generation vaccines ACAM 2000 and third generation vaccines based on the LC16m8 strain are reserve drugs. However, the established fact that the LC16m8 strain, when passaged in cell culture, spontaneously reverts to the original variant of the Lister strain led to genetic engineering work to delete the B5R gene to obtain the LC16m8Δ mutant, which is not capable of reversion. A vaccine based on the LC16m8Δ strain could technically be classified as a fourth generation drug, and taking into account the high immunogenicity and relative safety of this strain based on the results of preclinical studies, there is a real prospect of producing an advanced and effective reserve drug based on it. Thus, analysis of long-term data on the study of the LC16m8 vaccine indicates that this drug is superior to other analogues of the 1st, 2nd and 3rd generation in terms of effectiveness and safety. Further genetic engineering work with this strain, which made it possible to obtain a safe but immunogenic genovariant of the LC16m8Δ strain, is a clear example of a productive movement towards the development of safe and effective fourth generation vaccines.Keywords
This publication has 28 references indexed in Scilit:
- Equination (inoculation of horsepox): An early alternative to vaccination (inoculation of cowpox) and the potential role of horsepox virus in the origin of the smallpox vaccineVaccine, 2017
- Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient miceVaccine, 2015
- Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8Vaccine, 2015
- Vaccinia virus vaccines: Past, present and futureAntiviral Research, 2009
- Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8JAMA, 2009
- LC16m8: An attenuated smallpox vaccineVaccine, 2006
- Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challengeVaccine, 2006
- Structural Analysis of Vaccinia Virus DIs Strain: Application as a New Replication-Deficient Viral VectorVirology, 2002
- Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteinsVirology, 1991
- Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strainVaccine, 1987